Therefore, the well-established effect of skin allergens on Keap1-Nrf2-antioxidant response element (ARE) regulatory pathway activation, concomitantly with experimental evidence highlighting Nrf2 as an attractive molecular target in the context of AD, led us to hypothesize that skin allergens may have a positive and therapeutic role in AD. This evidence concerns the gene NFE2L2 and Alzheimer disease.